Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Prokidney (PROK) over the last 1 years, with Jun 2025 value amounting to $1.7 million.

  • Prokidney's Gains from Investment Securities rose 77.72% to $1.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.6 million, marking a year-over-year increase of 34.53%. This contributed to the annual value of $21.4 million for FY2024, which is 46.12% up from last year.
  • Latest data reveals that Prokidney reported Gains from Investment Securities of $1.7 million as of Q2 2025, which was down 94.46% from $30.4 million recorded in Q1 2025.
  • In the past 5 years, Prokidney's Gains from Investment Securities registered a high of $30.4 million during Q1 2025, and its lowest value of $246,000 during Q3 2022.
  • In the last 3 years, Prokidney's Gains from Investment Securities had a median value of $8.4 million in 2023 and averaged $11.9 million.
  • Data for Prokidney's Gains from Investment Securities shows a peak YoY soared of 2,841.82% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Prokidney's Gains from Investment Securities stood at $826,000 in 2022, then soared by 159.44% to $2.1 million in 2023, then spiked by 49.71% to $947,000 in 2024, then skyrocketed by 77.72% to $1.7 million in 2025.
  • Its Gains from Investment Securities was $1.7 million in Q2 2025, compared to $30.4 million in Q1 2025 and $947,000 in Q2 2024.